Visionary Holdings Inc. Reports Fiscal Year 2025 Annual Report
Rhea-AI Summary
Visionary Holdings (Nasdaq: GV) filed its Annual Report for fiscal 2025 (year ended Mar 31, 2025) outlining a strategic shift from education and real estate toward health management, anti-aging, and premium medical aesthetics alongside an AI-enabled education business. Total revenue was USD 5.04 million (-46.2% YoY); emerging health businesses contributed ~21.1% of revenue. The company reported a net loss of USD 15.75 million, including ~USD 4.70 million of asset impairment charges, and cited ~USD 54.50 million negative working capital and ongoing liquidity pressures. Management plans further commercialization, strategic collaborations, governance enhancements, and potential financings.
Positive
- Emerging health businesses generated ~21.1% of revenue
- Education gross margin of 64.4%
- Operating cash outflows decreased to USD 2.97M from USD 4.10M
- Investing cash inflow of USD 14.51M from asset dispositions supported liquidity
Negative
- Total revenue USD 5.04M, down 46.2% YoY
- Net loss of USD 15.75M including USD 4.70M asset impairments
- Approximately USD 54.50M negative working capital and loan defaults
- Real estate leasing contraction materially reduced core revenue
News Market Reaction
On the day this news was published, GV declined 1.60%, reflecting a mild negative market reaction. Argus tracked a peak move of +37.4% during that session. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $95K from the company's valuation, bringing the market cap to $6M at that time. Trading volume was exceptionally heavy at 15.5x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GV fell 1.6% while key peers were mixed: WAFU -1.83%, AMBO -7.5%, EEIQ +2.72%, KIDZ -4.43%. Momentum scanner flagged LXEH +4.26% and KIDZ +5.64%, indicating stock-specific factors for GV rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | Governance & strategy | Positive | -0.0% | Board changes, medical aesthetics pivot, and annual report filing timeline. |
| Dec 30 | Management change | Positive | -0.0% | New health-tech CEO and Nanjing sales entity to drive China execution. |
| Nov 10 | Product launch | Positive | -2.4% | Launch of stem cell anti-aging product line targeting Asian markets. |
| Nov 04 | Leadership overhaul | Positive | -3.2% | New chairman, senior team, and committees to standardize governance. |
| Oct 31 | AGM & results | Positive | +1.9% | AGM approvals, strong big-health growth metrics, and asset-liability update. |
Recent positive-sounding governance and strategic updates often saw flat-to-negative 24h price reactions, with only one of the last five news events aligning positively with price.
Over the last few months, GV has focused on governance renewal, strategic pivoting to high-end medical aesthetics, and laying groundwork for commercial execution. Events on Oct 31, 2025 and Nov 3, 2025 reshaped the board and committee structure, while a Nov 10, 2025 launch expanded stem cell-based offerings in Asia. Late-December announcements detailed partnerships and leadership changes. Today’s Form 20-F adds quantified revenue contraction, losses, and liquidity pressures to that strategic narrative.
Market Pulse Summary
This announcement detailed GV’s transition from education and real estate toward health management and premium medical aesthetics, while revealing a 46.2% revenue decline and a USD 15.75 million net loss for FY 2025. Early health-business revenues, modest gross-margin improvement, and reduced operating cash outflows contrast with significant negative working capital and loan defaults. Investors may watch execution in health segments, cash-generation trends, and further steps to stabilize the balance sheet.
Key Terms
form 20-f regulatory
AI-generated analysis. Not financial advice.
Highlighting Strategic Transformation and Early Commercial Progress in Emerging Health Businesses
TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (Nasdaq: GV) (the “Company”) today announced the disclosure of its Annual Report on Form 20-F for the fiscal year ended March 31, 2025, outlining the Company’s strategic transformation, business restructuring progress, and financial performance.
During the reporting period, the Company continued to advance its transition from a traditional education- and real estate-focused business toward a diversified platform centered on health management, anti-aging and premium medical aesthetics, complemented by its AI-enabled education business. Emerging health-related businesses generated initial revenue contributions during the fiscal year, representing early progress in the Company’s strategic repositioning and providing potential new growth avenues over the medium to long term.
The complete and official Annual Report on Form 20-F is included as an attachment to this press release.
Financial Highlights
For fiscal year 2025, total revenue was USD 5.04 million, representing a year-over-year decrease of
- Real estate leasing revenue of USD 2.80 million
- Education services revenue of USD 1.18 million
- Life sciences and health-related businesses, including health management, anti-aging, and medical aesthetics-related products and service-based offerings, generating USD 1.06 million
Revenue from emerging businesses accounted for approximately
The Company reported a net loss of USD 15.75 million, primarily reflecting one-time transformation-related investments, approximately USD 4.70 million in asset impairment charges, and financing-related costs, which management considers to be transitional in nature.
Gross margin improved modestly to
As of March 31, 2025, total assets amounted to USD 63.63 million. In response to certain loan defaults and approximately USD 54.50 million in negative working capital, the Company has continued to pursue measures including equity financing initiatives and negotiations with creditors regarding debt restructuring and extensions, with certain creditors having agreed to temporary extensions. Nevertheless, the Company continues to face liquidity and financing pressures, and management will continue to evaluate and implement prudent measures to improve its financial condition.
Business Developments and Strategic Transformation
Health Management Businesses
In the health management and anti-aging sector, the Company has pursued exploratory initiatives focused on health management and service-oriented offerings, including gastrointestinal health management and solutions. Through a business model combining platform development, strategic partners, and end-service delivery, the Company has advanced market testing and early-stage commercialization efforts in Asia. These initiatives remain subject to ongoing execution and validation.
Anti-Aging and Premium Medical Aesthetics Businesses
In the anti-aging and premium medical aesthetics sector, the Company is exploring service-driven medical aesthetics and health management solutions aligned with market demand in Asia and supported by North American medical resources.
During the reporting period, the Company established strategic collaborations with industry participants, including Jiangsu Yike Regenerative Medicine Technology Co., Ltd. and Anhui Weikang Kangling Medical Technology Co., Ltd. These collaborations are intended to support access to certain proprietary technologies and product resources with competitive industry positioning, and to facilitate the Company’s ongoing efforts to expand and develop its global premium medical aesthetics service network.
AI Education Business
The Company’s AI education business remained relatively stable. Through a hybrid online-offline model, the Company continued to offer Ontario Secondary School Diploma (OSSD) programs, vocational education, and academic pathway services, while maintaining cooperation with multiple Canadian public institutions to provide integrated education support services for international students.
CEO Commentary
Mr. Xiyong Hou, Chief Executive Officer of Visionary Holdings, commented:
“Fiscal year 2025 marked a critical phase in which the Company’s strategic transformation progressed from planning toward tangible execution. The initial revenue contributions generated by emerging businesses during the reporting period validated the practical feasibility of our transition toward health management, anti-aging, and premium medical aesthetics, and provided a foundation for subsequent development.
In the coming fiscal years, the Company will focus on high-potential segments within premium medical aesthetics and cellular rejuvenation-related businesses, advancing commercialization efforts and market expansion around Cellular Rejuvenation and Aesthetic Treatment-related products and services. Based on current market conditions, strategic planning, and execution assumptions, the Company believes it has the potential to drive this segment toward meaningful revenue scale over the next two years, subject to market dynamics, regulatory considerations, and execution progress.
At the same time, we remain committed to strengthening corporate governance and internal controls by enhancing financial and compliance capabilities, reinforcing enterprise-wide compliance practices, and improving audit committee oversight. Management will continue to execute with discipline and prudence, leveraging technological innovation, compliant operations, and service quality to support sustainable growth and create long-term value for shareholders.”
Outlook
Looking ahead, the Company intends to advance its development along the following directions:
- Continue to explore commercialization opportunities in health management, anti-aging, and premium medical aesthetics businesses, integrating global technology, market, and team resources through existing strategic collaborations and, subject to prudent evaluation, potential acquisitions or partnerships;
- Further optimize the AI education ecosystem by enhancing digital student management systems and steadily expanding marketing efforts in key Asian markets to support business stability and cash flow generation;
- Continue strengthening corporate governance and internal control systems, including the recruitment of experienced finance and compliance professionals, enhanced compliance training, and the normalization of audit committee operations, with the goal of improving financial reporting quality and operational transparency.
About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV's control, which may cause GV's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Contacts:
Visionary Holdings Inc.
Investor Relations
Email: IR@visionary.holdings
Telephone: +1 905-305-1881
Website: http://www.visionary.holdings
A PDF accompanying this announcement is available at: http://ml.globenewswire.com/Resource/Download/d60032a2-5d2f-4e04-80e9-6cd0271dec39
FAQ
What were Visionary Holdings (GV) full-year revenue and net loss for fiscal 2025?
How much of GV's revenue in fiscal 2025 came from emerging health businesses?
What liquidity and balance-sheet risks did Visionary Holdings (GV) disclose on Jan 13, 2026?
What strategic priorities did GV announce for the next two years in the 2025 annual report?
Did Visionary Holdings (GV) report any asset impairments or one-time costs in fiscal 2025?
